St Paul, MN, November 11, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 – 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson’s Disease, Nociceptive, Neuropathic, Post-operative and Inflammatory Pain.
Multiple sclerosis is a demyelinating disease of the CNS. Due to the clinical and pathological similarities of EAE and MS, EAE has been used as a model for the study of human demyelinating disease and is characterized by a relapsing-remitting disease course with subsequent progressive disability.
- MBP-induced EAE
- MOG-induced EAE
- PLP-induced EAE.
Gliosis is a proliferation of astrocytes in the central nervous system (CNS) in response to injury which results in scar formation. Astrocytes react to injury by hypertrophy and up-regulation of the glial-fibrillary acidic protein. Gliosis, along with neuronal loss, is a prominent feature of many diseases of the central nervous system.
Parkinon's Disease (PD) is a neurogenerative disorder characterized by reduction in striatial (DA) content caused by the loss of dopaminergenic neurons in the Substantia Nigra part compacta (SNpc) and their proportions to the striatum.
- Acute MPTP
- Chronic MPTP
MD Biosciences offers Nociceptive, Neuropathic and Inflammatory Pain models:.
- Tail Flick
- Visceral Pain
- Post-operative pain
- Chronic Constriction Injury (CCI, Bennett & Xie)
- Taxol induced Neuropathic Pain
- Spinal Nerve Ligation (Chung)
- STZ Diabetic Neuropathy
- Carrageenan Induced Inflammatory Pain
- Adjuvant (CFA) induced Inflammatory Pain
- Arthritic and Monoarthritic Pain.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.